|
 |
|
|
press releases |
|
|
|
|
|
 |
Jul-03, 2007 |
|
|
|
|
|
Dec-06, 2006 |
|
|
|
|
|
Oct-25, 2005 |
|
|
|
|
|
Oct-18, 2004 |
|
|
|
|
|
Dec-12, 2003 |
|
|
|
|
|
Apr-08, 2003 |
|
|
|
|
|
Aug-06, 2002 |
|
|
|
|
|
Jul-20, 2002 |
|
|
|
|
|
Jan-01, 2002 |
|
|
|
|
|
Jul-15, 2001 |
|
|
|
|
|
Jul-02, 2001 |
|
|
|
|
|
Dec-01, 2000 |
|
|
|
|
|
|
|
|
|
 |
|
Jul-03, 2007
Bicoll announces the signing of a new partnership with Genfit and the partial financing of a 3.2 million euro joint EuroTrans-Bio project by ERA-Net/ European Commission |
|
Munich, Germany - July 3rd, 2007 - The Bicoll GmbH, a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields, today announces the signing of a collaboration agreement with Genfit SA (ALGFT) (Lille, France), a biopharmaceutical company committed to drug discovery and development in the field of cardiovascular, inflammatory and metabolic disease.
Bicoll and Genfit will combine their strength in biopharmaceutical drug discovery and development to search for novel ligands binding to a well-characterized class of nuclear receptors that are relevant targets for diseases with an inflammatory component. These orphan nuclear receptors share structural features of classical steroid receptors but by definition lack identified natural or synthetic ligands.
The joint research project "OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites" will be based on the screening of the highly diversified library of plant metabolites established by the Bicoll Group. Bicoll will provide Genfit with a defined number of ProfilesTM. These property-sorted fractions are generated from plant extracts with Bicoll's robust, innovative separation system with a proprietary separation phase.
Bicoll further announces that the joint research proposal was selected for a partly and risk sharing support of the overall cost of 3.2 million Euro. Part of the funding is done by the EuroTrans-Bio/ERA-Net call for transnational research projects in the fields of health, agro/food and environment. Further partners for the research project are the University of Lille 2 (R&D department), France, and the University of Freiburg (R&D department), Germany.
"We are pleased to disclose the facts about the OLNORME project today, after the final agreement of our local national funding organization," commented Kai Lamottke, Managing Director of Bicoll.
"Small molecules from plants have long been of interest for their reliable ability to produce compounds with distinct biological or pharmacological properties. More than 50% of drugs on the market today are based on natural compounds as the active principle. This risk-sharing grant from the EU and German Government enables us further to demonstrate the successful integration of natural products screening via ProfilesTM in this distinguished disease area. The partner's assay will screen an estimated number of more than +100.000 natural compounds to deliver drug candidates for further development.
About the EuroTrans-Bio/ ERA-Net initiative
The EuroTrans-Bio initiative's goal is to support trans-national R&D private/private and private/public co-operations between companies, especially SMEs, and academic labs by coordinating their national or regional public funding programs. Thus, EuroTrans-Bio fosters economic and academic biotech players in sharing risks, costs and skills related to innovation in order to develop in a more efficient way new products and technologies that could reach the market in the short/medium term.
EuroTrans-Bio is a consortium between 17 Members (Agencies and Ministries) from 9 European countries and regions. The coordination of the EuroTrans-Bio initiative is funded by the European Commission in the ERA-Net scheme.
About Bicoll
Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus is on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and additional services, like custom synthesis, are tailored to its customers' needs to accelerate the development process of new pharmaceuticals.
The Bicoll Group participates in several confidential research projects and provides its services to a number of international clients of various fields of interest, e.g. pharmaceutical and agrochemical industry. The Bicoll Group comprises two legal entities: Bicoll GmbH in Munich, Germany and, since 2001, Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai. Bicoll currently employs 25 people at both locations. |
|
|
|
|
|
|
Dec-06, 2006
Ricerca Biosciences, LLC and The Bicoll Group enter significant collaboration agreement |
|
December 6th, 2006, Concord, OH, USA/Munich, Germany/ Shanghai, P.R. China - Ricerca Biosciences, LLC and the Bicoll Group today announced the signing of a collaboration agreement. The agreement builds on a long-term relationship between the two companies.
Ricerca and Bicoll will combine their strengths in MedChem Services to offer innovative solutions that streamline drug discovery and development. With Ricerca's network of business development representatives throughout the United States, a close interaction to clients can be secured. Additionally, Ricerca will leverage Bicoll's medicinal chemistry and natural product chemistry technology for drug discovery to North American clients.
"We believe that the access to Bicoll's unique natural product chemistry technology as well as its competence in supportive reporting and IP protection will further strengthen our broad portfolio as a successful solution provider for product and process development and testing services, commented Thomas Bradshaw, Chief Executive Officer of Ricerca. "Bicoll's strong and reliable MedChem Services, conducted in China, will allow us to provide our clients with additional valuable support in drug discovery."
"Joining forces, Bicoll and Ricerca will be able to provide high medicinal, natural product, and custom synthetic chemistry services with a competitive price range to their clients," stated Dr. Kai Lamottke, General Manager of Bicoll (Shanghai) Co. Ltd. "As a state-of-the-art R&D company for high-tech natural product chemistry and drug discovery, the Bicoll Group has experienced an intensive growth spurt over the past few years – with the strong marketing partnership of Ricerca within North America we will now be able to provide our services together not only to European pharmaceutical customers, but to clients worldwide."
Ricerca Biosciences, LLC, located on a 46-acre site in Concord, Ohio, is a contract drug discovery and development company, offering extensive drug discovery and development services that improve the odds of converting drug discovery leads to drug candidates, moving candidates over preclinical hurdles to IND filing. Ricerca also supports clinical trials through GMP API manufacture and bioanalytical services.
Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus is on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and additional services, like custom synthesis, are tailored to its customers' needs to accelerate the development process of new pharmaceuticals.
The Bicoll Group comprises two legal entities: Bicoll GmbH in Munich, Germany and, since 2001, Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang Hi-Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai. |
|
| Refs.: |
> BioPortfolio online, Dec. 08, 2006
Drug Discovery Online, Dec. 07, 2006
Chemie.de, Dec. 13, 2006 |
|
|
|
|
|
|
|
|
Oct-25, 2005
Bicoll (Shanghai) Co. Ltd. expands its laboratory facilities within Zhangjiang Hi-Tech Park/Shanghai |
|
October 25th, 2005, Shanghai - Bicoll Biotechnology (Shanghai) Co. Ltd., announced today that it has expanded its laboratory facilities for R&D drug discovery and development within the Zhangjiang Hi-Tech Park, Shanghai. Now nearly the double size of lab space is at Bicoll's disposal.
Especially Bicoll's custom synthesis unit will take over a large part of the newly provided facilities to expand its services.
"As a state-of-the-art R&D company for high-tech natural product chemistry and drug discovery, the Bicoll Group has experienced an intensive growth spurt over the last years" stated Dr. Kai Lamottke, general manager of Bicoll (Shanghai) Co. Ltd.; "The decision to move to more spacious laboratories contributes to Bicoll's expansion strategy for the next years. With the new spacious laboratory facilities, we will make sure to serve our partners best and continue to deliver products in time, budget and multi-gram scale. Additionally it opens up the possibility to build-up new partnerships in custom synthesis as well as drug discovery cooperations."
About Bicoll
Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus lays on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and additional services like custom synthesis are tailored to its customers' needs to accelerate the development process of new pharmaceuticals. |
|
|
|
|
|
|
Oct-18, 2004
Break even for Bicoll (Bicoll reaches after-tax profit in its third year of operations) |
|
October 18th, 2004, Munich/Germany - Bicoll GmbH, Munich announced today that it has generated an after-tax profit in the last fiscal year, in its third year of operation. Bicoll is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions. Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology.
"We are very proud in having achieved a positive result within only 3 years after the company's foundation, especially looking at an ever changing, difficult market place for the biotech business" said Dr. Kai Lamottke, managing director of Bicoll GmbH.
"This performance contains a lot of value for us - especially as Bicoll was founded as a 'post-boom' company. It places Bicoll in a stable position from where we can target our second phase of growth to release the full potential of the company", he continues. "Our positive cash flows support the favorable long-term prospects for Bicoll. Based on our existing developments and processes we will extend our existing capacities but also further push ahead in our own in-house pre-clinical drug development projects in cancer, diabetes, Alzheimer, and tuberculosis. To complement our internal research efforts we are planning to expand our research co-operations as well. We are very much looking forward to exhilarating and busy times." |
|
| Refs.: |
> SCRIP World Pharmaceutical News,
issue Oct. 21st-2004 |
|
|
|
|
|
Get the pdf-file here: (59 kB, language: English) |
|
|
|
|
|
> BioVenture View, 12 Nov 2004,
Vol 19, No 21/22, page 8 |
|
|
|
|
|
Get the pdf-file here: (67 kB, language: English) |
|
|
|
|
|
> transkript, 10. Jahrgang, 11/04, page 8 |
|
|
|
|
|
Get the pdf-file here: (80 kB, language: German) |
|
|
|
|
|
|
|
|
Dec-12, 2003
The Bicoll Group successfully completes a Public Private Partnership (PPP) project with the Deutsche Investitions- und Entwicklungsgesellschaft mbH (DEG) |
|
 December 12th, 2003, Munich – The Bicoll GmbH, announced today that it has successfully completed a Public Private Partnership (PPP) project in the field of environmental protection in China. Bicoll carried out this extensive and ambitious project together with its public partner Deutsche Investitions- und Entwicklungsgesellschaft mbH (DEG) in coordination function for the Federal Ministry for Economic Cooperation and Development (BMZ). The costs of this roughly 500 000 € project were shared 55/45 between Bicoll and the BMZ (resp. DEG).
Most of the Chinese rich floral biodiversity is increasingly threatened by human activities. The direct, non-regulated collection of herbs and plants for Traditional Chinese Medicine is only one of the facts that endanger rare species.
With DEG's commitment to carry 45% of the total costs, Bicoll could start a unique educational program to demonstrate the economic value of preservation to local people making them more sensitive to the necessity of protecting biodiversity.
"Bicoll elaborated a completely new business model to prove that innovative and modern research and development of novel, western-standard pharmaceuticals and the conservation of biodiversity can go hand in hand" explained Dr. Christian Haug, chairman of board of directors of Bicoll Biotechnology (Shanghai) Co. Ltd. "Though the starting materials for Bicoll's innovative drug development process are generated from endemic Asian plants, the protection of biodiversity is guaranteed through Bicoll's highly efficient use of resources. The collection of larger amounts of plants is not attempted for further drug development as only a hand full of the rare natural sources is necessary for Bicoll's lead structure library and screening systems."
With DEG's help, Bicoll was able to establish one of the most modern research laboratories for drug development in China. As all value-added services of Bicoll's drug development process are carried out in China, the company not only guarantees a sustainable financial flow to local communities but also provides Western technology and transfers know-how into a developing country.
"We appreciate DEG's confidence and esteem of our project" expressed Dr. Christian Haug his thanks to Claudia Wink and Renate Katenkamp (DEG) who presented to him a golden badge for the successful conclusion of Bicoll's PPP project.
About Bicoll
Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus lays on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and services are tailored to its customers' needs to accelerate the development process of new pharmaceuticals.
About Deutsche Investitions- und Entwicklungsgesellschaft mbH (DEG) and PPP projects
The DEG is one of Europe's largest development finance institutions specializing in long-term project and corporate financing for private sector investments in Asia, Latin America, Africa as well as Central and Eastern Europe. DEG has so far cooperated with more than 950 private enterprises and is currently active in about 80 countries, having financed a total of more than 4.2 billion €. In addition, DEG, among other institutions, executes the Public Private Partnership program of the German Federal Ministry for Economic Development and Cooperation (BMZ).
PPP projects are expected to make a contribution to the national development and have a beneficial impact on the environment and social relations. The private enterprise acts as project leader that transfers technology and knowledge but benefits economically in the long run. |
|
|
|
|
|
|
Apr-08, 2003
Bicoll GmbH, Munich/Germany makes appointments to its advisory board |
|
April 08, 2003, Munich/Germany - Bicoll GmbH, Munich announced today the four members of the company's Advisory Board. With Thorsten Bach, Ph.D., Hardy Debuch, Ph.D., K. Peter C. Vollhardt, Ph.D., and Sina Afra, MBA, the Bicoll-Group will strengthen the company's sustainable strategy for modern drug design using its proprietary technology platform for natural product chemistry, combinatorial chemistry and screening techniques.
"The Bicoll-Group looks forward to working with each of these qualified individuals, who gained strong records in their fields of interest." said Dr. Kai Lamottke, managing director of Bicoll GmbH and board member of Bicoll Biotechnology (Shanghai) Co. Ltd.. "As we are currently successfully implementing our unique business model on the global market, our advisory board will certainly contribute with its high expertise to a profitable business growth in the international perspective."
Thorsten Bach is Professor of Organic Chemistry at the Technical University, Munich. His special interest is dedicated to the total synthesis of bioactive natural products utilizing photo- and organometallic chemistry. In cooperation with industrial and academic partners the research group of Thorsten Bach seeks to find new leads for modern drug research and to elucidate structure-activity-relations. In 2001 Thorsten Bach was awarded the Astra Zeneca Research Award.
Professor Bach gained his thorough experience in organic chemistry with G.A. Olah (1987-1988), M.T. Reetz (1988-1991), D.A. Evans (1991-1992) and D. Hoppe (1992-1996).
So far Professor Bach authored more than 85 publications and serves as Editor for the journal Synthesis.
Hardy Debuch runs his own international consultancy for the pharmaceutical industry market, DHD Unternehmensberatung AG. His extensive experience has been gained in more than 30 years assuming leading positions in pharmaceutical research and marketing with E. Merck, Darmstadt/Germany, Röhm Pharma, Germany and Schwarz Pharma, Germany. In his role as chair and CEO of Schwarz Pharma's U.S. and Italian divisions, Hardy Debuch was leading Schwarz Pharma from a German-oriented company to a global market player.
K. Peter C. Vollhardt is Professor in the Department of Chemistry, University of California at Berkeley, Senior Principal Investigator at the Chemical Science Division, Lawrence Berkeley National Laboratory, and Assistant Dean to the College of Chemistry. As one of the world's foremost organic chemists, he was awarded the Adolf Windaus Medal of the German Chemical Society (1983), a Humboldt Senior Scientist Award (1985 and 1992), the ACS Award in Organometallic Chemistry (1987), the Otto Bayer Prize 1990, the ACS Arthur C. Cope Scholar Award 1991, a Japan Society for Promotion of Science Award 1995, the Stiftung Buchkunst Prize (Germany) 1996, the ACS Edward Leete Award 1999, and the Medal of the University Aix-Marseille (2000). Professor Vollhardt has more than 30 years of experience in the application of transition metals to enable the synthesis of complex natural and unnatural products. His outstanding scientific work led to over 265 scientific papers. In addition he authored the standard college textbook on organic chemistry and serves as Chief Editor for the journal Synlett.
Sina Afra has more than 10 years experience in the consulting business. He is Senior Manager for the Frankfurt office of Bearing Point (former KPMG) where he belongs to the department World Class Finance. Sina Afra is specialized in the area of Value Based Management, Planning and Cost Accounting. Beside these, he has expertise in conducting international market and valuation studies. Sina Afra also gained experience in competition analysis for diverse leading international chemicals companies and edited the Value Based Management Study "Concepts of Shareholder Value- an analysis of the DAX 100 companies". |
|
| Refs.: |
> SCRIP World Pharmaceutical News,
issue April 29th-2003, Feature: People |
|
|
|
|
|
Get the pdf-file here: (77 kB, language: English) |
|
|
|
|
|
> transkript, 9. Jahrgang, 6/03, page 70 |
|
|
|
|
|
Get the pdf-file here: (65 kB, language: German) |
|
|
|
About the Bicoll-Group
The Bicoll group is an international biopharmaceutical enterprise with a head office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
The company provides an innovative, fast and flexible approach to modern drug research.
Bicoll provides optimized, high-quality small molecule libraries (BILOBAC N) for drug discovery cooperations with companies of the biopharmaceutical industry. The submitted libraries are specially designed for the target protein of the partner's indication field to provide highest success rate. The starting material is generated through Bicoll's access to Asian plant resources.
Bicoll's two core technologies BIFRAC N and BIPRESELECT enable the company to accelerate the development process of new drug candidates. BIFRAC N is an isolation and separation system to detect biologically active compounds. By applying the BIPRESELECT process, the company identifies selected ADME criteria. Thus Bicoll is able to sort out non-successful drug candidates, which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third.
Currently, Bicoll is initiating its own in-house drug development projects, one of which is in the area of central nervous system disorders. |
|
|
|
|
|
|
Aug-06, 2002
German-Sino Biotechnology co-operation Bicoll to complete its first year in Shanghai successfully |
|
Bicoll Biotechnology (Shanghai) Co. Ltd., a 100% subsidiary of Bicoll GmbH, Germany, has successfully completed the Chinese company's build-up process in Shanghai / P.R. China within one year only. The general manager of Bicoll Biotechnology (Shanghai) Co. Ltd., Dr. Kai Lamottke, is highly satisfied about the prompt implementation of the company's proprietary technology platform. First products have already been launched into exclusive co-operations and partnerships. Within the next three years, Bicoll Biotechnology (Shanghai) Co. Ltd. is planning to extend the company's research and development location from up to date 10 employees to over 50.
The Bicoll group is an internationally orientated biopharmaceutical enterprise with a headquarters office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
The company provides an innovative, fast and flexible approach to modern drug research. Bicoll's competence stretches from natural product chemistry to combinatorial chemistry, screening techniques, structural biology, own developed novel deconvolution technology, isolation strategies and structural elucidation.
Bicoll provides optimized, high-quality small molecule libraries (BILOBAC N) for drug discovery co-operations with companies of the biopharmaceutical industry. The submitted libraries are specially designed for the target protein of the partner's indication field to provide highest success rate. The starting material is generated through Bicoll's access to Asian plant resources.
Bicoll's two core technologies BIFRAC N and BIPRESELECT enable the company to accelerate the development process of new drug candidates. BIFRAC N is an isolation and separation system to detect biologically active compounds. By applying the BIPRESELECT process, the company identifies selected ADME criteria. Thus Bicoll is able to sort out non-successful drug candidates, which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third.
Currently, Bicoll is initiating its own in-house drug development projects, one of which is in the area of central nervous system disorders. |
|
| Refs.: |
> Handelsblatt Newsletter-online,
"Trends in Biotechnologie", Aug-09, 2002. |
|
|
|
|
|
Get the pdf-file here:
(55 kB, language: German)
|
|
|
|
|
|
|
|
|
Jul-20, 2002
100 000 Euro support from Bavarian ministry for Bicolls innovative concept in drug discovery |
|
Soon, patients who thought that they suffer from diseases with no cure available can expect effective treatment. This was one of the motivation, for the Bavarian ministry for science, research and arts to support two of the founders of the biotechnology company Bicoll (Munich, Germany) with a 100 000 Euro fund (Fluegge – program) for transforming promising academic invention into successful business. Through this Bavarian grant two of the founders of Bicoll, Kai Lamottke, Ph.D. (Technical University Munich) and Jun Xie, Ph.D. (University of Munich), can also use the unique facilities located at their home universities to apply it at their ongoing research at Bicoll.
Today, drug development companies cannot satisfy the continuous growth in demand of new, high-quality active molecules addressing newly found drug targets. Bicoll solves this bottleneck requirement: building on the selective forces of evolution in nature. Their invention of an innovative, flexible and fast concept will be able to speed up modern drug discovery, selecting highly qualified small molecules for further development. |
|
| Refs.: |
> transkript 8-9/02, Seite 20 |
|
|
|
|
|
Get the pdf-file here: (76 kB, language: German) |
|
|
|
|
|
> BioVenture View 03.09.2002,
Vol. 17, No. 17/18, page 3 |
|
|
|
|
|
|
|
|
|
|
Jan-01, 2002
Bicoll announces the appointment of Kai Lamottke as General Manager for Bicoll Biotechnology (Shanghai) Co. Ltd. |
|
Dr. Kai Lamottke has been appointed General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. (Shanghai). He has more than six years of experience in synthetic organic research. Lamottke received his "Diplom" in chemistry from the University of Münster, Germany, where he carried out his theoretical work, whereas the practical work was done in a joint exchange program at the University of California, Berkeley.
Kai Lamottke holds a doctoral degree in organic chemistry from the University of Munich, Germany. Prior to joining Bicoll he was working for a rational drug discovery company, 4SC AG, in constructing the combinatorial chemistry division as Project Leader [99-00]. Dr. Lamottke currently also holds a research position at the Technical University of Munich, Germany. |
|
| Refs.: |
> C&EN, January 21, 2002, page 65 |
|
|
|
|
|
Get the pdf-file here: (140 kB, language: English) |
|
|
|
|
|
> Shanghai Daily, Vol. 3, No. 656. |
|
|
|
|
|
|
|
|
|
|
Jul-15, 2001
Bicoll and Deutsche Investitions- und Entwicklungsgesellschaft mbH to work on PPP-project (Public-Private-Partnership) in China |
|
| Bicoll announced today to carry out a public-private-partnership-project. Bicoll's public partner in that special environmental protection project will be the Deutsche Investitions- und Entwicklungsgesellschaft mbH (DEG). The DEG has a coordination function for the Federal Ministry for Economic Co-operation and Development (BMZ). The costs of this 350 000 USD project are shared 55/45 between Bicoll and the BMZ. Bicoll will invest in a unique training and education program in China related to modern drug discovery. The PPP-project will support Bicoll to speed up its growth in China. |
|
| Refs.: |
> Handelsblatt Newsletter-online,
"Trends in Biotechnologie", Sep-06, 2002. |
|
|
|
|
|
|
|
> Deutsch-Chinesisches WirtschaftsForum /
German-Chinese Business Forum
[Pharmaceutical Industry], Vol. 2/02, page 16-18. |
|
|
|
|
|
Get the pdf-file here:
Download (192 kB, language: English) |
|
|
|
|
|
> Auslandskurier 12/01, page 28. |
|
|
|
|
|
Get the pdf-file here:
Download (140 kB, language: German) |
|
|
|
|
|
> China Contact 09/01, page 14-15.
Read this article here. (Language: German) |
|
|
|
|
|
About Bicoll
Bicoll is a growing biotechnology company providing an innovative, flexible and fast concept for modern drug research. Bicoll's mission is to accelerate the developing process of new drug candidates.
By combining research in combinatorial chemistry, screening techniques, natural product chemistry and synthesis Bicoll is able to embrace a leading position in drug development. With its proprietary techniques Bicoll will create a vast number of pharmaceutical like compounds available for high-throughput bioassays. Moreover Bicoll launches into proprietary projects involving development and optimization of new drug candidates. |
|
|
|
|
|
|
Jul-02, 2001
Foundation of Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China |
|
Foundation of Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China
Bicoll GmbH, Germany, announces the foundation of Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China. The Sino part of the company is a 100% subsidiary of Bicoll GmbH.
"China is one of the most exciting emerging pharmaceutical markets" said Dr. Kai Lamottke, member of the board of directors, "The country has been maintaining the production and sales of pharmaceuticals at a double-digit growth annually since the mid-1980's. Especially the biotech industry in China starts to follow the highly successful US model. The Chinese pharmaceutical market is split between domestic producers (most of them state owned) and China-foreign joint ventures to produce over 800 chemical drugs to satisfy the needs of its more than one billion people. With Chinas acceptance in the WTO and the current efforts of Chinese policy makers, the capacity of the national pharmaceutical industry will increase dramatically. This encouraged Bicoll to establish its business in Asia's hottest biotechnology region. This step will bring Bicoll among the forerunners of biotech companies in a constantly changing international landscape of modern drug development."
Bicolls research center is located in the "Drug-Development-Valley", Shanghai / Pudong and the headquarters office in Munich, Germany. Further international expansion of the Bicoll group is under way. |
|
| Refs.: |
> Wenhui Bao, August 17th 2001, page 8. |
|
|
|
|
|
|
|
Dec-01, 2000
Foundation of Bicoll GmbH, Munich/Germany |
|
Bicoll GmbH has been founded in Munich, Germany, one of Europe's most interesting biotech "hotspots". Bicoll's mission is to accelerate the developing process of new drug candidates.
The growing biotechnology company provides an innovative, flexible and fast concept for modern drug research. Bicoll provides experienced manpower and the required expertise in defined research fields. By combining research in combinatorial chemistry, screening techniques, natural product chemistry and synthesis Bicoll is able to embrace a leading position in drug development. With its proprietary techniques, such as BIFRAC N, Bicoll will create a vast number of pharmaceutical like compounds available for high-throughput bioassays. Moreover Bicoll launches into proprietary projects involving development and optimization of new drug candidates. |
|
|
|
|
|
|
